CanSino Biologics Inc Capital Reinvestment Ratio

Latest as of December 2021: 0.35x

CanSino Biologics Inc capital reinvestment ratio. CanSino Biologics Inc (CJH) has a Capital Reinvestment Ratio of 0.35x as of December 2021, meaning it reinvests 0% of its operating cash flow (€806.73 Million) in capital expenditures (€284.07 Million). Check how aggressively does CanSino Biologics Inc reinvest cash to assess the company's total reinvestment commitment from operating cash flow.

Capital Reinvestment Ratio

0.35x
Capex / Operating Cash Flow

Operating Cash Flow

€806.73 Million
EUR

Capital Expenditures

€284.07 Million
EUR

Data as of

Dec 2021
Most recent filing

Capital Reinvestment Ratio of CanSino Biologics Inc (2021–2025)

Capital reinvestment ratio of CanSino Biologics Inc from 2021 to 2025. This chart tracks CanSino Biologics Inc's Capital Reinvestment Ratio across 2 annual periods. Also explore net asset momentum of CanSino Biologics Inc to track the company's year-over-year net asset growth rate.

CanSino Biologics Inc Capital Reinvestment Ratio by Year (2021–2025)

CanSino Biologics Inc capital reinvestment ratio by year from 2021 to 2025. For the full cash flow conversion analysis, see CJH cash flow conversion.

Year Reinvestment Ratio Operating CF (EUR) Capital Expenditures YoY Change
2025 3.13x €77.86 Million €243.90 Million ▲ +433.8%
2021 0.59x €2.05 Billion €1.20 Billion —
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow